Expression of MAGE-A genes
Patients . | Pathology (according to the REAL classification) . | Fraction of MAGE-positive samples . |
---|---|---|
B-cell NHL (n = 29) | Small lymphocytic lymphoma | 0/2 |
Mantle cell lymphoma | 0/5 | |
Follicle center lymphoma | 0/14 | |
Marginal zone B-cell lymphoma | 0/1 | |
Diffuse large B-cell lymphoma | 0/6 | |
Plasmacytoma/plasma cell lymphoma | 0/1 | |
Total B-cell NHL | 0/29 | |
T-cell NHL (n = 9) | Precursor T-lymphoblastic lymphoma | 0/3 |
Anaplastic large cell lymphomas | 1/5* | |
Lymphoepithelioid peripheral T-cell lymphoma | 1/1* | |
Total T-cell NHL | 2/9 (22.2%) | |
HD (n = 18) | Type I (lymphocyte predominance) | 0/2 |
Type II (nodular sclerosis) | 4/8* | |
Type III (mixed cellularity) | 1/7* | |
Type IV (lymphocyte depletion) | 0/1 | |
Total HD | 5/18 (27.8%) |
Patients . | Pathology (according to the REAL classification) . | Fraction of MAGE-positive samples . |
---|---|---|
B-cell NHL (n = 29) | Small lymphocytic lymphoma | 0/2 |
Mantle cell lymphoma | 0/5 | |
Follicle center lymphoma | 0/14 | |
Marginal zone B-cell lymphoma | 0/1 | |
Diffuse large B-cell lymphoma | 0/6 | |
Plasmacytoma/plasma cell lymphoma | 0/1 | |
Total B-cell NHL | 0/29 | |
T-cell NHL (n = 9) | Precursor T-lymphoblastic lymphoma | 0/3 |
Anaplastic large cell lymphomas | 1/5* | |
Lymphoepithelioid peripheral T-cell lymphoma | 1/1* | |
Total T-cell NHL | 2/9 (22.2%) | |
HD (n = 18) | Type I (lymphocyte predominance) | 0/2 |
Type II (nodular sclerosis) | 4/8* | |
Type III (mixed cellularity) | 1/7* | |
Type IV (lymphocyte depletion) | 0/1 | |
Total HD | 5/18 (27.8%) |
Expression of MAGE-A genes was determined semiquantitatively with RT-PCR as explained in the legend to Figure 1.
Levels of expression of the individual MAGE-A genes in the positive samples were as follows: 1 anaplastic large cell lymphoma:MAGE-A1+, A2+, A3+, A4+, andA12+; 1 lymphoepithelioid cell lymphoma: MAGE-A4±; 4 HD type II: 1 MAGE-A4++ (HD4), 1 MAGE-A4+ (HD5), and 2MAGE-A4± (HD3, HD6); and 1 HD type III: MAGE-A4+ (HD17).